$NRSNW
NeuroSense Therapeutics Ltd.
Nasdaq · Pharmaceutical Preparations · Herzliya, Israel
NRSNW chart
What traders are saying about $NRSNW
Latest postsNeuroSense Therapeutics Ltd. news
- NeuroSense Therapeutics Signs Strategic Collaboration Agreement To Advance Primec Supply For ALS Patients
TradingView ·
- PrimeC could reach patients before marketing approval under NeuroSense (NRSN)'s new advisory deal.
Stock Titan ·
- NeuroSense Therapeutics Ltd. Estimates – NASDAQ:NRSNW
TradingView ·
- NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
Yahoo Finance ·
- NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Yahoo Finance ·
- NeuroSense Provides Update on Nasdaq Listing Compliance
Yahoo Finance ·
- NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Yahoo Finance ·
- NeuroSense Provides Business Update and Progress for the First Half of 2026
Yahoo Finance ·
- NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Yahoo Finance ·
- NeuroSense Issues CEO Letter to Shareholders
Yahoo Finance ·
- NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Yahoo Finance ·
NeuroSense Therapeutics Ltd. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$11.1M | -$10.2M | -$10.1M | -$10.5M |
| Diluted EPS | $-0.44 | $-0.54 | $-0.74 | $-0.91 |
| Total assets (year end) | $1.0M | $4.6M | $3.2M | $7.7M |
| Cash and equivalents (year end) | $166,000 | $3.4M | $2.6M | $3.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
About NeuroSense Therapeutics Ltd.
- Ticker
- NRSNW (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Herzliya, Israel
- Incorporated in
- Israel
- Fiscal year end
- December 31
- SEC CIK
- 1875091
Frequently asked questions
What exchange is NeuroSense Therapeutics Ltd. listed on?
NeuroSense Therapeutics Ltd. trades on the Nasdaq under the ticker symbol NRSNW.
What industry is NeuroSense Therapeutics Ltd. in?
NeuroSense Therapeutics Ltd. is classified by the SEC under "Pharmaceutical Preparations".
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd.'s business address on file with the SEC is in Herzliya, Israel.
When does NeuroSense Therapeutics Ltd.'s fiscal year end?
NeuroSense Therapeutics Ltd.'s fiscal year ends on December 31.